1. Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells.
- Author
-
Liu YT, Chen L, Li SJ, Wang WY, Wang YY, Yang QC, Song A, Zhang MJ, Mo WT, Li H, Hu CY, and Sun ZJ
- Subjects
- Humans, Cell Line, Tumor, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Pyruvate Dehydrogenase Acetyl-Transferring Kinase metabolism, Animals, Proto-Oncogene Proteins c-akt metabolism, Neoplasms metabolism, Neoplasms pathology, Mice, Protein Serine-Threonine Kinases metabolism, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors metabolism, Promoter Regions, Genetic genetics, Wnt Signaling Pathway, Copper metabolism, beta Catenin metabolism, Copper-Transporting ATPases metabolism, Copper-Transporting ATPases genetics, Transcription Factor 4 metabolism
- Abstract
Cuproptosis is characterized by the aggregation of lipoylated enzymes of the tricarboxylic acid cycle and subsequent loss of iron-sulfur cluster proteins as a unique copper-dependent form of regulated cell death. As dysregulation of copper homeostasis can induce cuproptosis, there is emerging interest in exploiting cuproptosis for cancer therapy. However, the molecular drivers of cancer cell evasion of cuproptosis were previously undefined. Here, we found that cuproptosis activates the Wnt/β-catenin pathway. Mechanistically, copper binds PDK1 and promotes its interaction with AKT, resulting in activation of the Wnt/β-catenin pathway and cancer stem cell (CSC) properties. Notably, aberrant activation of Wnt/β-catenin signaling conferred resistance of CSCs to cuproptosis. Further studies showed the β-catenin/TCF4 transcriptional complex directly binds the ATP7B promoter, inducing its expression. ATP7B effluxes copper ions, reducing intracellular copper and inhibiting cuproptosis. Knockdown of TCF4 or pharmacological Wnt/β-catenin blockade increased the sensitivity of CSCs to elesclomol-Cu-induced cuproptosis. These findings reveal a link between copper homeostasis regulated by the Wnt/β-catenin pathway and cuproptosis sensitivity, and suggest a precision medicine strategy for cancer treatment through selective cuproptosis induction., (© 2024. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.)
- Published
- 2024
- Full Text
- View/download PDF